Kyle Glover

Kyle Glover i

DuPont Company - Wilmington / United States
Natural Sciences / Molecular Biology & Genetics
AD Scientific Index ID: 4385518
-
person_outline Kyle Glover's MOST POPULAR ARTICLES
1-) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialO Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ...The Lancet 397 (10285), 1637-1645, 2021815*2021
2-) Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysisO Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ...The Lancet 400 (10349), 359-368, 20222262022
3-) In silico toxicology protocolsGJ Myatt, E Ahlberg, Y Akahori, D Allen, A Amberg, LT Anger, A Aptula, ...Regulatory Toxicology and Pharmacology 96, 1-17, 20181972018
4-) Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their …CH Yang, KP Glover, X HanToxicological sciences 117 (2), 294-302, 20101762010
5-) Organic anion transporting polypeptide (Oatp) 1a1-mediated perfluorooctanoate transport and evidence for a renal reabsorption mechanism of Oatp1a1 in renal elimination of …CH Yang, KP Glover, X HanToxicology letters 190 (2), 163-171, 2009962009